Cargando…

A functional role of LEFTY during progesterone therapy for endometrial carcinoma

BACKGROUND: The left-right determination factor (LEFTY) is a novel member of the TGF-β/Smad2 pathway and belongs to the premenstrual/menstrual repertoire in human endometrium, but little is known about its functional role in endometrial carcinomas (Em Cas). Herein, we focused on LEFTY expression and...

Descripción completa

Detalles Bibliográficos
Autores principales: Fei, Wu, Kijima, Daiki, Hashimoto, Mami, Hashimura, Miki, Oguri, Yasuko, Kajita, Sabine, Matsumoto, Toshihide, Yokoi, Ako, Saegusa, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740891/
https://www.ncbi.nlm.nih.gov/pubmed/29268772
http://dx.doi.org/10.1186/s12964-017-0211-0
_version_ 1783288101247909888
author Fei, Wu
Kijima, Daiki
Hashimoto, Mami
Hashimura, Miki
Oguri, Yasuko
Kajita, Sabine
Matsumoto, Toshihide
Yokoi, Ako
Saegusa, Makoto
author_facet Fei, Wu
Kijima, Daiki
Hashimoto, Mami
Hashimura, Miki
Oguri, Yasuko
Kajita, Sabine
Matsumoto, Toshihide
Yokoi, Ako
Saegusa, Makoto
author_sort Fei, Wu
collection PubMed
description BACKGROUND: The left-right determination factor (LEFTY) is a novel member of the TGF-β/Smad2 pathway and belongs to the premenstrual/menstrual repertoire in human endometrium, but little is known about its functional role in endometrial carcinomas (Em Cas). Herein, we focused on LEFTY expression and its association with progesterone therapy in Em Cas. METHODS: Regulation and function of LEFTY, as well as its associated molecules including Smad2, ovarian hormone receptors, GSK-3β, and cell cycle-related factors, were assessed using clinical samples and cell lines of Em Cas. RESULTS: In clinical samples, LEFTY expression was positively correlated with estrogen receptor-α, but not progesterone receptor (PR), status, and was inversely related to phosphorylated (p) Smad2, cyclin A2, and Ki-67 levels. During progesterone therapy, expression of LEFTY, pSmad2, and pGSK-3β showed stepwise increases, with significant correlations to morphological changes toward secretory features and decreased Ki-67 values. In Ishikawa cells, an Em Ca cell line that expresses PR, progesterone treatment reduced proliferation and induced increased expression of LEFTY and pGSK-3β, although LEFTY promoter regions were inhibited by transfection of PR. Moreover, inhibition of GSK-3β resulted in increased LEFTY expression through a decrease in its ubiquitinated form, suggesting posttranslational regulation of LEFTY protein via GSK-3β suppression in response to progesterone. In addition, overexpression or knockdown of LEFTY led to suppression or enhancement of Smad2-dependent cyclin A2 expression, respectively. CONCLUSION: Upregulation of LEFTY may serve as a useful clinical marker for the therapeutic effects of progesterone for Em Cas, leading to inhibition of tumor cell proliferation through alteration in Smad2-dependent transcription of cyclin A2. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12964-017-0211-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5740891
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57408912018-01-03 A functional role of LEFTY during progesterone therapy for endometrial carcinoma Fei, Wu Kijima, Daiki Hashimoto, Mami Hashimura, Miki Oguri, Yasuko Kajita, Sabine Matsumoto, Toshihide Yokoi, Ako Saegusa, Makoto Cell Commun Signal Research BACKGROUND: The left-right determination factor (LEFTY) is a novel member of the TGF-β/Smad2 pathway and belongs to the premenstrual/menstrual repertoire in human endometrium, but little is known about its functional role in endometrial carcinomas (Em Cas). Herein, we focused on LEFTY expression and its association with progesterone therapy in Em Cas. METHODS: Regulation and function of LEFTY, as well as its associated molecules including Smad2, ovarian hormone receptors, GSK-3β, and cell cycle-related factors, were assessed using clinical samples and cell lines of Em Cas. RESULTS: In clinical samples, LEFTY expression was positively correlated with estrogen receptor-α, but not progesterone receptor (PR), status, and was inversely related to phosphorylated (p) Smad2, cyclin A2, and Ki-67 levels. During progesterone therapy, expression of LEFTY, pSmad2, and pGSK-3β showed stepwise increases, with significant correlations to morphological changes toward secretory features and decreased Ki-67 values. In Ishikawa cells, an Em Ca cell line that expresses PR, progesterone treatment reduced proliferation and induced increased expression of LEFTY and pGSK-3β, although LEFTY promoter regions were inhibited by transfection of PR. Moreover, inhibition of GSK-3β resulted in increased LEFTY expression through a decrease in its ubiquitinated form, suggesting posttranslational regulation of LEFTY protein via GSK-3β suppression in response to progesterone. In addition, overexpression or knockdown of LEFTY led to suppression or enhancement of Smad2-dependent cyclin A2 expression, respectively. CONCLUSION: Upregulation of LEFTY may serve as a useful clinical marker for the therapeutic effects of progesterone for Em Cas, leading to inhibition of tumor cell proliferation through alteration in Smad2-dependent transcription of cyclin A2. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12964-017-0211-0) contains supplementary material, which is available to authorized users. BioMed Central 2017-12-21 /pmc/articles/PMC5740891/ /pubmed/29268772 http://dx.doi.org/10.1186/s12964-017-0211-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Fei, Wu
Kijima, Daiki
Hashimoto, Mami
Hashimura, Miki
Oguri, Yasuko
Kajita, Sabine
Matsumoto, Toshihide
Yokoi, Ako
Saegusa, Makoto
A functional role of LEFTY during progesterone therapy for endometrial carcinoma
title A functional role of LEFTY during progesterone therapy for endometrial carcinoma
title_full A functional role of LEFTY during progesterone therapy for endometrial carcinoma
title_fullStr A functional role of LEFTY during progesterone therapy for endometrial carcinoma
title_full_unstemmed A functional role of LEFTY during progesterone therapy for endometrial carcinoma
title_short A functional role of LEFTY during progesterone therapy for endometrial carcinoma
title_sort functional role of lefty during progesterone therapy for endometrial carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740891/
https://www.ncbi.nlm.nih.gov/pubmed/29268772
http://dx.doi.org/10.1186/s12964-017-0211-0
work_keys_str_mv AT feiwu afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT kijimadaiki afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT hashimotomami afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT hashimuramiki afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT oguriyasuko afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT kajitasabine afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT matsumototoshihide afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT yokoiako afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT saegusamakoto afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT feiwu functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT kijimadaiki functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT hashimotomami functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT hashimuramiki functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT oguriyasuko functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT kajitasabine functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT matsumototoshihide functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT yokoiako functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma
AT saegusamakoto functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma